Gastrooesophageal Cancer clinical trials

Explore recruiting gastrooesophageal cancer clinical trials.

Recruiting gastrooesophageal cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gastrooesophageal Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C

Norway, Italy, Germany, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

DANTE / FLOT8 A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness (MO30039/MO43340)– The IKF-DANTE Trial A Trial of AIO in collaboration with SAKK

Germany

Phase II and Phase III (Integrated) EU CTIS Study details

INTEGRATE IIb A Randomised Phase III Open Label Study of regorafenib + nivolumab vs standard chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

Austria, Germany, Italy, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

The PRESTO Trial - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therapies for HER2+, resectable esophagogastric adenocarcinoma

Germany, Austria

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma - A phase II trial of the AIO study group – PHERFLOT

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Gastrooesophageal Cancer trials by city

Gastrooesophageal Cancer in Toronto Gastrooesophageal Cancer in Vancouver Gastrooesophageal Cancer in Montreal Gastrooesophageal Cancer in Calgary Gastrooesophageal Cancer in Edmonton Gastrooesophageal Cancer in Ottawa Gastrooesophageal Cancer in Winnipeg Gastrooesophageal Cancer in Quebec City Gastrooesophageal Cancer in Hamilton Gastrooesophageal Cancer in Kitchener Gastrooesophageal Cancer in London Gastrooesophageal Cancer in Halifax Gastrooesophageal Cancer in New York Gastrooesophageal Cancer in Los Angeles Gastrooesophageal Cancer in Chicago Gastrooesophageal Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease